The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

International Society for Pharmacoeconomics and Outcomes Research, Inc
May 13th – 16th 2025, Montreal, Canada
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Sleep-wake disorders
POSTER
The Economic Burden of Narcolepsy in the United States: Matched Analysis of National Health and Wellness Survey Data
AUTHOR(S)

Kiran P. Maski,1,2 Michael J. Doane,3 M. Janelle Cambron-Mellott,4 Shakiba Eslamimehr,5 Adam Jauregui,6 Wilbur P. Williams, III3

Embargo date: 05-16-2025 Embargo time: 23:59 EDT
Sleep-wake disorders
Schizophrenia
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

Embargo date: 05-16-2025 Embargo time: 23:59 EDT
Schizophrenia
Bipolar Disorder
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

Embargo date: 05-16-2025 Embargo time: 23:59 EDT
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

Embargo date: 05-16-2025 Embargo time: 23:59 EDT
Schizophrenia